Treatment-By-Genotype Effects In Drug Trials

Why Model Treatment Effects by Genotype?

A randomized drug trial can estimate whether treatment effects differ among participants with different genotypes. The key is to distinguish two questions: what is the treatment effect within each genotype group? and how much does that treatment effect differ between groups? Regression models answer both, provided the genotype coding and the contrasts of interest are specified clearly.

The examples use a quantitative outcome measured after treatment, with larger values representing greater improvement. The same contrast logic applies to other outcomes, but the meaning and scale of a coefficient depend on the outcome model. This tutorial focuses on formulating and estimating the contrasts, not on comparing interaction scales.

Randomization supports a causal interpretation of the treatment contrast within genotype groups when both assignments are possible in each group, outcomes are defined consistently under either assignment, and the analysis respects the trial's assignment and follow-up. In particular, there must be participants assigned to both arms in each genotype group whose effect is to be estimated. Genotype itself is not randomized, so differences between genotype groups should not be interpreted as effects caused by changing genotype.

Categorical Genotypes: Estimate Each Group's Treatment Effect

Suppose a biallelic variant has three genotype groups: \(G=0\), \(G=1\), and \(G=2\), representing zero, one, and two copies of a specified allele. If the scientific aim is to allow each genotype group its own treatment effect, represent genotype categorically. Taking \(G=0\) as the reference group, a linear regression model is

Here \(I(\cdot)\) equals 1 when its condition is true and 0 otherwise. The model allows a separate mean outcome in each of the six treatment-by-genotype cells. The group-specific treatment effects follow by subtracting the control-arm mean from the drug-arm mean:

Thus, \(\delta_1=\tau_1-\tau_0\) and \(\delta_2=\tau_2-\tau_0\) are differences between treatment effects, each relative to the reference genotype. They are not the treatment effects in groups 1 and 2. A joint test of no treatment-by-genotype interaction is \(H_0:\delta_1=\delta_2=0\). Under the usual large-sample regression approximation, a Wald test uses the estimated interaction coefficients and their covariance matrix and is compared with a chi-squared distribution with 2 degrees of freedom.

Additive Dosage: A Prespecified Trend Model

A different model treats dosage \(G\) as the numerical count 0, 1, or 2. The additive interaction model is

For dosage \(g\), the model's treatment effect is \(\tau_g=\beta_T+\delta g\). In this specification, \(\beta_T\) is the estimated treatment effect at dosage 0, and \(\delta\) is the change in treatment effect for each additional copy of the allele. The model assumes a linear trend in the treatment effect across dosage: the difference between effects at dosages 1 and 0 equals the difference between effects at dosages 2 and 1. This is a modeling restriction, not a consequence of randomization.

Other prespecified codings answer other questions. For example, a dominant coding \(Z=I(G\geq 1)\) groups carriers together and compares their treatment effect with that in non-carriers. A recessive coding \(Z=I(G=2)\) compares genotype 2 with genotypes 0 and 1 combined. With either coding, including \(T Z\) estimates the difference in treatment effects between the two coded groups. The coding should match the scientific question and be chosen before examining outcome differences; trying several codings and reporting only the most favorable result can overstate the evidence.

Estimation, Uncertainty, and Adjusted Models

In a linear regression, the fitted coefficients are estimated from participant-level outcomes. A requested treatment effect is a linear combination of those coefficients. If \(\hat{\boldsymbol{\beta}}\) is the coefficient vector and a contrast is \(c^\mathsf{T}\hat{\boldsymbol{\beta}}\), its estimated standard error is

The covariance terms matter: adding two coefficient estimates does not generally mean adding their standard errors. For a sufficiently large sample and an appropriate regression variance estimate, an approximate 95% confidence interval for the contrast is the estimate plus or minus 1.96 standard errors. This interval describes uncertainty from repeated sampling under the model and analysis; it does not assign a 95% probability to the fixed treatment effect being inside the particular interval.

A model may include prespecified baseline covariates to improve precision or address features of the randomization design. The estimated treatment effect for genotype \(g\) must still be calculated as the model-predicted drug outcome minus the model-predicted control outcome for that genotype. If treatment effects also vary with covariates, the contrast may depend on covariate values; an average genotype-specific effect then requires averaging the predicted treatment contrasts over a stated covariate distribution. Standard errors should use a covariance estimator appropriate to the design and model; for example, a robust estimator can be used when constant residual variance is not credible.

What the Interaction Test Does—and Does Not—Say

A test of no interaction addresses whether the modeled treatment effects are equal across the genotype groups specified by the coding. For the categorical model with three groups, the null is the joint restriction \(\delta_1=\delta_2=0\). For the additive model, the null is \(\delta=0\), which tests for a linear dosage trend in treatment effects under that model. These are not the same hypothesis: an arbitrary pattern across three genotype groups can depart from equality without following a linear trend.

An interaction test is not a test that the drug works in any particular subgroup. Conversely, evidence that a treatment effect differs between genotypes does not by itself show that the treatment effect is beneficial in one group and harmful in another. Estimate and report the group-specific treatment effects and their uncertainty alongside the interaction contrast. A nonsignificant interaction test also does not prove that treatment effects are identical; the estimate's uncertainty and the trial's ability to distinguish effects matter.

Reporting the Result in Context

A clear report names the treatment comparison, outcome and units, genotype coding, subgroup treatment-effect estimates, and interaction contrast. For example: “In the hypothetical trial, the estimated drug-control difference in improvement was 4 points for genotype 0 and 2 points for genotype 1; the genotype 1 treatment effect was 2 points lower than the genotype 0 effect.” If inference is reported, include the relevant confidence interval or test result and identify whether it concerns a subgroup treatment effect or a difference between treatment effects. This wording keeps the randomized treatment comparison distinct from nonrandomized differences between genotypes.